H.C. Wainwright raised the firm’s price target on TG Therapeutics (TGTX) to $70 from $60 and keeps a Buy rating on the shares after the company reported Q1 earnings. The firm, which is increasing its U.S. Briumvi and total revenue estimates, cites both increased estimates and greater confidence in 2026 performance for its raised target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX: